The FDA’s New Tzield Approval Fundamentally Alters Stage 3 Pediatric Type 1 Diabetes Management
Episode Summary
The FDA’s approval of teplizumab for newly diagnosed pediatric Type 1 diabetes marks a shift from insulin replacement toward preserving remaining beta-cell function through immunotherapy.